€500 Million in 4 Years: Why Health-Tech is Creating the Next Billion-Dollar Companies

About this episode

The Evolution of Healthcare Investment in Europe

Manuel Grossmann, founder of Amino Collective, has a clear mission: to make Europe a leading hub for healthcare and bio-investments. In his conversation with Unicorn Bakery, he explains why this sector holds the potential for the next billion-dollar companies and which strategies are crucial for success.

Why Europe Lags Despite Excellent Science

Europe faces a paradox: while scientific excellence is undisputed, there are very few companies valued at over €500 million in the healthcare and bio sector. Grossmann identifies several reasons for this discrepancy:

• –Fragmented markets: Europe consists of many smaller markets with different regulatory requirements
• –Risk-averse investment culture: Many traditional VCs shy away from the longer development cycles in healthcare
• –Lack of specialized funds: Generalist VCs often don't understand the complexity of bio-tech investments

Thesis-Driven Investing as a Success Factor

Amino Collective pursues a thesis-driven approach that fundamentally differs from traditional VC strategies. Instead of investing opportunistically, the team develops clear hypotheses about the future of the healthcare sector and actively seeks companies that support these theses.

This approach requires a deep balance between scientific understanding and entrepreneurial expertise. Grossmann emphasizes that successful healthcare investments must consider both scientific validity and commercial potential.

The Role of University Spinouts

A particular focus lies on university spinouts, which often produce the most innovative technologies. However, these companies face unique challenges:

Building scientific teams: Recruiting and managing highly specialized scientists requires different management approaches than traditional tech startups.

The right skill mix: Successful bio-tech companies need a combination of scientific expertise, regulatory know-how, and entrepreneurial capabilities.

Why Small, Specialized Funds are the Future

Grossmann makes a compelling argument that theme-specific funds often achieve better results than large generalist funds. The advantages:

• –Deeper understanding: Specialized teams better understand the nuances of the healthcare market
• –Better networks: Focused funds have stronger connections to relevant experts and partners
• –More efficient decision-making: Smaller teams can act faster and more flexibly

The Transformation of the European VC Model

The venture capital landscape in Europe is undergoing a fundamental transformation. Traditional models with high management fees are increasingly being questioned. Instead, innovative funds like Amino Collective focus on performance-oriented structures that prioritize carry over management fees.

This development reflects a generational shift: new fund managers are willing to take more risk and think long-term, rather than relying on safe management income.

Munich vs. Berlin: The Battle for Healthcare Supremacy

Interesting is Grossmann's assessment of the German hub landscape. While Berlin is often considered Germany's startup capital, he sees Munich as the natural hub for healthcare and bio-tech investments:

• –University landscape: Munich and the Bavaria region have a strong concentration of life science universities
• –Industrial base: Proximity to established pharma and medtech companies creates synergies
• –Capital availability: Munich traditionally has better access to institutional capital

AI as the Game-Changer of the Next 50 Years

Particularly exciting is Grossmann's forecast about the impact of Artificial Intelligence in healthcare. He sees AI not just as a supporting technology, but as a fundamental catalyst that will transform the entire industry.

The application areas are diverse:

• –Drug discovery: AI can drastically accelerate drug development
• –Diagnostics: More precise and faster diagnoses through machine learning
• –Personalized medicine: Tailored therapies based on individual data

Why Europe Can Take Off Now

Despite current challenges, Grossmann is optimistic about Europe's future in healthcare investment. The conditions are right:

• –Regulatory clarity: Europe is developing clear frameworks for bio-tech innovation
• –Talent pool: The scientific excellence of European universities is undisputed
• –Capital market evolution: New fund structures and investment approaches are emerging

The next few years will be decisive in whether Europe can fully realize its potential in the healthcare sector. With pioneers like Manuel Grossmann and Amino Collective blazing new trails in the investment space, the chances are good that Europe will indeed produce the next healthcare billion-dollar companies.